Key takeaways
- Ketamine is a Schedule III controlled substance with recognized potential for misuse.
- Research on medically supervised ketamine treatment finds low rates of craving, dose escalation, and dependence.
- Recreational ketamine use involves much higher doses, no monitoring, and unrestricted access. This makes it a very different risk profile.
- Heavy long-term recreational use is linked to serious bladder and urinary problems.
- Structured dosing, in-office monitoring, and provider oversight are the safeguards that matter most.
Ketamine has recognized potential for misuse and is a Schedule III controlled substance. Yet research on medically supervised treatment for mental health conditions finds low rates of craving, dose escalation, or dependence. Risk rises substantially with recreational use, higher doses, and unsupervised access. Clinical settings reduce that risk through structured dosing, monitoring, and ongoing provider oversight.
If you are considering ketamine for a mental health condition, asking whether ketamine is addictive is a reasonable question and a responsible one. The drug has a reputation as a misused substance, and that reputation is not unearned. What often gets lost is that that risk is significantly lowered when administered during a supervised clinical visit.
Is ketamine addictive when used as a medical treatment?
The evidence suggests the risk is low when ketamine is given under clinical supervision at therapeutic doses. It is not zero, which is why it deserves monitoring.
A systematic review published in the Journal of Psychopharmacology examined addiction risk among adults receiving ketamine for depression and concluded that treatment has a relatively safe profile when administration is medically supervised, doses are conservative, and patients are monitored over time.
A more recent systematic review of 30 clinical and preclinical studies reached a similar conclusion. Across controlled, clinically supervised settings, researchers found minimal evidence of craving, intentional dose escalation, misuse, or illicit use.
The authors of both reviews are careful about what this does and does not mean. The research base is still developing, and studies have not always used standardized measures for dependence. Low risk is not the same as no risk, and that distinction matters.
What makes recreational ketamine use different from clinical treatment?
Almost everything. The dose, the setting, the frequency, and the access are all different, and each of those differences affects risk.
Recreational use typically involves substantially larger amounts than a therapeutic dose. In recreational settings, it is usually taken without medical oversight and often repeated in a single session. There is no clinician tracking response, no ceiling on how much is used, and no limit on how often. Frequency and dose escalation are the mechanisms by which dependence develops, and both are structurally constrained in a clinical setting.
Clinical treatment inverts that. Doses are fixed and prescribed. Administration happens in the office. Sessions are scheduled at set intervals rather than taken on demand. A provider assesses your response and adjusts the plan.
This is also why heavy chronic recreational use carries risks that supervised treatment does not typically produce, including ketamine-induced bladder and urinary tract damage.
“What the research shows, and what I see in practice, is that people receiving supervised treatment for depression don’t develop that pattern of craving,” said Joshua Flatow, MD, medical director and chief psychiatrist at Pacific Mind Health. “The controls we build around it — the dosing, the monitoring, the schedule — exist precisely to keep it that way.”
Why is ketamine a controlled substance?
Ketamine is classified as a Schedule III controlled substance under the federal Controlled Substances Act. This means it has accepted medical uses alongside a potential for abuse and dependence.
Esketamine, sold as Spravato® and derived from ketamine, carries the same Schedule III classification. Its US Food and Drug Administration labeling includes a boxed warning covering the potential for abuse and misuse, along with sedation and dissociation.
That classification is the reason Spravato can only be administered in a healthcare setting that has been certified through a federal Risk Evaluation and Mitigation Strategy program (REMS). This means a healthcare provider is required to monitor each patient for at least two hours after every dose. It is never dispensed for home use. Pacific Mind Health belongs to the REMS program.
Those requirements exist because regulators took the abuse potential seriously, not because the treatment is unsafe when those requirements are followed.
What safeguards reduce the risk?
Several, and they are worth asking any provider about directly.
- In-office administration and monitoring. Doses given and observed on site remove the possibility of unsupervised escalation.
- Structured dosing schedules. A defined protocol with set intervals, rather than dosing on demand.
- Screening for substance use history. Providers should ask about past or current substance use disorders before starting treatment.
- Ongoing response assessment. A provider tracking whether the treatment is working, and adjusting or stopping it if it is not.
- Integration with broader care. Ketamine works best as one part of a plan that includes therapy and medication management.
Who should be cautious about ketamine treatment?
Ketamine is not appropriate for everyone, and a history of substance use is a meaningful factor in that decision.
A personal history of ketamine misuse or an active substance use disorder warrants careful discussion with your provider before starting. That does not automatically rule treatment out, as clinicians weigh it against the severity of your depression and what else has been tried, but it changes how closely treatment should be monitored.
Certain medical conditions also matter, including uncontrolled high blood pressure and some cardiovascular and liver conditions. Your provider will review your full history before recommending treatment.
If you are struggling with substance use alongside depression, tell your provider. Both conditions are treatable, and treating one while ignoring the other rarely works.
Looking for Spravato or ketamine treatment near you?
Pacific Mind Health offers Spravato (esketamine) and ketamine therapy for treatment-resistant depression, major depressive disorder, and more.
Located in Southern California and serving patients across the state, Pacific Mind Health was founded by Joshua Flatow, MD, a board-certified psychiatrist and published research author.
Ready to take the next step? Schedule a free consultation today to see if Spravato or ketamine is right for you.
Frequently asked questions
Is ketamine addictive when prescribed for depression?
Research on medically supervised ketamine treatment finds low rates of craving, dose escalation, and dependence. Two recent systematic reviews of clinical studies reported minimal evidence of misuse when ketamine was given at therapeutic doses under clinical supervision. The risk is not zero, which is why providers screen for substance use history and monitor patients throughout treatment.
Is Spravato addictive?
Spravato® (esketamine) is a Schedule III controlled substance, and its labeling carries a boxed warning that includes the potential for abuse and misuse. Because of this, it can only be administered in a federally certified healthcare setting, with monitoring for at least two hours after each dose. It is never dispensed for patients to take home.
How is clinical ketamine different from recreational ketamine?
The dose, setting, and frequency all differ. Clinical treatment uses smaller, fixed doses administered on a set schedule with provider monitoring. Recreational use typically involves much larger amounts, taken repeatedly without oversight or dosing limits. Those differences are what drive the difference in addiction risk.
Can I get ketamine treatment if I have a history of substance use?
It depends on your circumstances and requires an honest conversation with your provider. A history of substance use does not automatically disqualify you, but it does affect how closely treatment should be monitored and whether other options should be tried first. Your provider will weigh it against the severity of your symptoms and your treatment history.
